Inmune Bio INMB
NASDAQ INMB
$1.46 -0.08 (-5.19%)
At close: Oct 23, 2026 · 4:00 PM EDT

Inmune Bio (INMB) Amortization of Deferred Charges (2021 - 2024)

Updated

Analysis

Inmune Bio (INMB) Amortization of Deferred Charges (2021 - 2024) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,137.66 Bn 1,106.24 Bn 19.71 Bn
2 Johnson & Johnson 636.13 Bn 556.00 Bn 17.30 Bn
3 AbbVie 505.28 Bn 478.39 Bn 12.70 Bn
4 Merck 358.10 Bn 312.48 Bn 12.21 Bn
5 Novartis Ag 292.59 Bn 256.58 Bn 11.24 Bn
6 Astrazeneca 265.81 Bn 239.50 Bn 12.86 Bn
7 Amgen 237.53 Bn 192.93 Bn 7.24 Bn
8 Gilead Sciences 194.67 Bn 168.86 Bn 6.22 Bn
9 Pfizer 171.17 Bn 117.82 Bn 10.94 Bn
10 Inmune Bio 39.14 Mn -53.11 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2024 6,000.00
Sep 30, 2024 15,000.00
Jun 30, 2024 24,000.00
Mar 31, 2024 34,000.00
Dec 31, 2023 45,000.00
Sep 30, 2023 54,000.00
Jun 30, 2023 58,000.00
Mar 31, 2023 67,000.00
Dec 31, 2022 68,000.00
Sep 30, 2022 58,000.00
Jun 30, 2022 57,000.00
Mar 31, 2022 56,000.00
Dec 31, 2021 57,000.00
Sep 30, 2021 53,000.00
API Access

Inmune Bio Amortization of Deferred Charges API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=amortization-of-deferred-charges&ticker=INMB&period=max&api_key=YOUR_API_KEY